Pure Global AI
NCT06034314Not yet recruiting

Oral Dronabinol-HIV

Investigation of the Effects of Cannabis on the Immune-genome in People With HIV
Yale UniversityPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
HIV
Drug/Device/Intervention
Dronabinol Capsules
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Yale University
Location
New Haven, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Oct 01, 2023
End date
Oct 01, 2027
Enrollment
160 participants
Primary outcome

Change in Dronabinol-induced transcriptome profile in blood using single cell (sc)RNA-seq

Summary

The purpose of this study is to define the mechanisms of cannabis on the genome of people
 with HIV who use cannabis. The investigator aims to better understand the effect of
 Dronabinol on immune and inflammatory functions, and whether these changes are HIV-status
 dependent. This research may better inform public health policy regarding cannabis use.
 Depending on the results, additional studies may also build upon this research to develop
 more effective and specific treatments for cannabis use associated disorders.

ICD-10 classifications
Human immunodeficiency virus [HIV] diseaseHuman immunodeficiency virus [HIV] disease resulting in other conditionsHIV disease resulting in other viral infectionsUnspecified human immunodeficiency virus [HIV] diseaseHuman immunodeficiency virus [HIV] disease resulting in other specified diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06034314
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06034314 through Pure Global AI's free database. This Phase 1 trial is sponsored by Yale University and is currently Not yet recruiting. The study focuses on HIV. Target enrollment is 160 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.